Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

NCT03592706 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

HepatoCellular Carcinoma
Liver Cancer

Interventions

BIOLOGICAL: IKC (Immune Killer Cells)
PROCEDURE: TACE (Transcatheter Arterial Chemoembolization)

Sponsor

Ivy Life Sciences, Co., Ltd

Collaborators

[object Object]